Chimerix Investor Conference Presentation Deck

Adult Case Study • 54-year-old thalamic H3 K27M DMG diagnosed in Nov 2018 First-line therapy: radiation and temozolomide ● ● Second-line therapy: 625mg weekly ONC201 monotherapy initiated May 2019 Corticosteroid elimination and radiographic regression over >1.5 years of therapy PS: absolute value Tumor size: % change from baseline Corticosteroid use: % change from baseline 29 100 80 60 40 20 0 0 3 Corticosteroid Use 6 9 Months from First Dose 12 Performance Status Tumor Size 15 18 Pre-ONC201 baseline 12.9 months on ONC201 18.5 months on ONC201 © 2021 Chimerix, Inc

View entire presentation